USFDA opens door to $30M market for India’s Strides Shasun’s HIV-1 infection tablets

India’s Bangalore-based Strides Shasun Limited, the subsidiary of Acrolab, has received approval from the United States Food & Drug Administration (USFDA) for Abacavir Tablets, for the treatment of HIV-1 infection.

The US market for Abacavir, for which the FDA has issued approval, is approximately $30 Million.

The product of USP, 300 mg According to IMS data, will be manufactured at the Company’s USFDA approved facility at Bangalore and marketed by Strides in the US Market.

Abacavir Tablets, used for the treatment of HIV-1 infection in combination with other antiretroviral agents, will be launched immediately.